DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially, with another 20 to 25% cured with salvage therapy. Efforts are ongoing to tailor therapy to particular genetic lesions.
No takes yet. Share an insight, caveat, or question.
Sehn et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: